Rising Pricing Pressure And Regulatory Hurdles Will Impair GI Prospects

Key Takeaways

• Margin pressure is mounting amid global price sensitivity, stricter reimbursement, and high R&D costs, limiting Phathom's growth and profitability prospects.
  
• Heavy dependence on a narrow GI drug pipeline exposes Phathom to significant concentration risk and future revenue uncertainties.
  
• Extended exclusivity, robust prescription growth, operational efficiencies, and pipeline expansion position Phathom for sustained, diversified growth and enhanced long-term profitability in a favorable market.

Catalysts

A biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases.

• Demand for Phathom's products is likely to be challenged by intensifying global price sensitivity and ongoing cost containment efforts in healthcare, leading to persistent downward pressure on drug pricing and reimbursements. This is expected to erode net margins and limit top-line revenue growth even as unit sales rise.
  
• Rising regulatory scrutiny and increasing hurdles for new gastrointestinal drug approvals are set to make clinical development more expensive and time-consuming, which may delay the commercialization of both existing pipeline candidates and lifecycle management assets-dragging on both future revenues and long-term earnings potential.
  
• Phathom remains heavily reliant on a narrow pipeline centered on acid-related GI drugs, creating significant concentration risk; failure to demonstrate superior long-term safety or efficacy compared to current and future competitors-including generics and biosimilars-would expose the company to revenue volatility and compress earnings stability well beyond 2026.
  
• Despite current revenue growth in the GI segment, shifting demographic trends such as declining birth rates and evolving dietary patterns could ultimately stagnate or shrink the addressable patient population for gastrointestinal disorders, capping Phathom's growth prospects and limiting future revenue expansion.
  
• Ongoing high research and development plus commercialization expenses, coupled with uncertain adoption rates in both the GI and primary care settings, threaten Phathom's ability to reach sustainable profitability, potentially forcing additional dilutive capital raises and perpetuating recurring net losses.

Phathom Pharmaceuticals Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• This narrative explores a more pessimistic perspective on Phathom Pharmaceuticals compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
• The bearish analysts are assuming Phathom Pharmaceuticals's revenue will grow by 49.9% annually over the next 3 years.
• The bearish analysts assume that profit margins will increase from -76.8% today to 21.1% in 3 years time.
• The bearish analysts expect earnings to reach $145.3 million (and earnings per share of $2.18) by about June 2029, up from -$157.3 million today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as $561.6 million.
• In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 11.3x on those 2029 earnings, up from -5.2x today. This future PE is lower than the current PE for the US Pharmaceuticals industry at 15.2x.
• The bearish analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.11%, as per the Simply Wall St company report.

Risks

• The granted VOQUEZNA exclusivity into 2033, with potential extensions through pediatric exclusivity and new indications such as EoE, significantly delays generic competition, supporting durable premium pricing and margin sustainability over the next decade and enhancing long-term revenue visibility.
  
• Strong growth in prescriptions and rapid adoption among gastroenterologists, the segment with highest need and prescribing power, indicate a robust product-market fit that positions Phathom for substantial and sustained revenue growth as sales force efforts are refocused on high-volume specialist prescribers.
  
• Recent cost-cutting measures, including the elimination of inefficient direct-to-consumer promotions and vendor optimization, have led to marked reductions in operating expenses without impacting core sales activity, improving operating leverage and accelerating the path toward profitability, which should be reflected in net income improvements.
  
• The EoE (eosinophilic esophagitis) program and potential pediatric studies provide clear levers for both pipeline expansion and exclusivity extension, offering Phathom the ability to diversify its revenue streams and reduce single-product risk, while also increasing the addressable patient pool in future years and supporting higher long-term earnings stability.
  
• Secular trends such as the persistent unmet need among GERD patients not well controlled by PPIs, growth in the GI therapy market due to aging demographics and lifestyle factors, and the high barriers for traditional competitors (as evidenced by delayed generic entry) suggest a favorable demand and pricing environment that can drive strong top-line and bottom-line growth over the long term.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bearish price target for Phathom Pharmaceuticals is $13.62, which represents up to two standard deviations below the consensus price target of $23.7. This valuation is based on what can be assumed as the expectations of Phathom Pharmaceuticals's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $29.0, and the most bearish reporting a price target of just $13.0.
• In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $689.8 million, earnings will come to $145.3 million, and it would be trading on a PE ratio of 11.3x, assuming you use a discount rate of 7.1%.
• Given the current share price of $10.37, the analyst price target of $13.62 is 23.9% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.